• Santosh S Bhujbal, Minal M Kad, and Vinita C Patole.
• Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune, India. Santosh.bhujbal@dypvp.edu.in.
• Ir J Med Sci. 2023 Oct 1; 192 (5): 241724262417-2426.

AbstractAlzheimer's disease (AD) is a neurological condition that affects millions of individuals around the world and for which there are few effective therapies. Dementia is characterized by the formation of senile plaques and neurofibrillary tangles, which is followed by neurotoxicity, which results in memory loss and mortality. Pathogenesis occurs several years before the onset of disease. As the disease-modifying drugs are most effective in the early stages of Alzheimer's disease, biomarkers for early detection of disease and their development are crucial. This review discusses the diagnostic utility, benefits, and limitations of traditional techniques such as neuroimaging, cognitive testing, positron emission tomography, and biomarkers, as well as the novel techniques such as artificial intelligence, machine learning, immunotherapy, and blood test approaches for early detection, understanding, and treatment of AD.© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.

11 keywords...

hide…